Shares of Elanco Animal Health Inc. ELAN, +2.76% surged 1.5% in morning trading Tuesday, putting them on track to snap a four-day losing streak, after the animal health company reported better-than-expected second-quarter earnings, but trimmed the top end of its full-year revenue guidance range, citing an increased headwind from African Swine Fever and the expected disruption of certain injectable cattle products. The company said earlier that it swung to net income of $35.9 million, or 10 cents a share, from a loss of $62.8 million, or 21 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS was 28 cents, above the FactSet consensus of 26 cents. Revenue rose 1% to $781.6 million, to beat the FactSet consensus of $781.0 million, as revenue for companion animal disease prevention rose 4%, companion animal therapeutics increased 22% and food animal future protein and health grew 2%, while food animal ruminants and swine fell 9%. For 2019, Elanco narrowed its adjusted EPS guidance range to $1.04 to $1.10 from $1.02 to $1.12–the FactSet consensus is $1.09–and revised its revenue outlook to $3.08 billion to $3.12 billion from $3.08 billion to $3.14 billion. The stock, which had lost 9.6% over the past four sessions, has lost 4.4% year to date, while the S&P 500 SPX, +1.48% has gained 16.5%.